Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 1...

Full description

Saved in:
Bibliographic Details
Published in:Open Forum Infect Dis
Main Authors: Alosaimy, Sara, Jorgensen, Sarah C J, Lagnf, Abdalhamid M, Melvin, Sarah, Mynatt, Ryan P, Carlson, Travis J, Garey, Kevin W, Allen, David, Venugopalan, Veena, Veve, Michael, Athans, Vasilios, Saw, Stephen, Yost, Christine N, Davis, Susan L, Rybak, Michael J
Format: Artigo
Language:Inglês
Published: Oxford University Press 2020
Subjects:
Brief Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060146/
https://ncbi.nlm.nih.gov/pubmed/32161775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa051
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items